Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidnarulex and Cemiplimab in Refractory Microsatellite Stable Colorectal Cancer
NCT07147231Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pidnarulex in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Aug 2026; status: recruiting.
02
Drugs
pidnarulex
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07147231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147231.